Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.
NVAX
$10.06
+$0.69 +7.36%

Novavax jumps 6% on cancer vaccine speculation, but real news is a new royalty model from partner approvals.

Market News
01 Sep 2026
24/7 Wall Street
View Source
Bullish
pluang ai news

Novavax shares rose 6% amid retail trader speculation about its Matrix-M adjuvant being used in cancer vaccines. However, the actual significant development was a quiet announcement last week that its partners received approvals for the 2026-2027 seasonal COVID-19 vaccine formulation, making Novavax eligible for royalty payments without commercial infrastructure. This royalty model, tied to partner sales led by Sanofi and Takeda, offers a steady revenue stream, while oncology applications remain exploratory with no confirmed deals. Investors should focus on upcoming milestones tied to vaccine trials and manufacturing transfers rather than speculative oncology hopes.

More News (NVAX)

Novavax partners get approval for Nuvaxovid targeting COVID-19 XFG variant for 2026-2027 season

Novavax partners get approval for Nuvaxovid targeting COVID-19 XFG variant for 2026-2027 season

Novavax's partners Sanofi and Takeda have secured approvals for the Nuvaxovid vaccine targeting the SARS-CoV-2 XFG variant for the 2026-2027 COVID-19 vaccination season in key markets including the U.S., EU, and Japan. This protein-based, non-mRNA va...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App